PubMed Health⌕ Search

Biomedical subjects

A Duroux

Publications and source records attributed to A Duroux.

7 recordsLinked to original sources

Tracheobronchial surface active material in cystic fibrosis.

Surface active material potentially present in the airway is difficult to analyse due to the tight binding of surfactant components to mucins. A surface active sol-fraction was obtained from sputum of patients with cystic fibrosis (CF), analysed and compared with the sol-fraction from sputum of tracheomized, non-CF patients. The release of phospholipids from CF sputum was relatively fast being completed within minutes, temperature dependent and averaged 5.6 +/- 2.2% of total phospholipid mass. In comparison to sputum, the phospholipid composition of the sol fraction was the same except for a lower percentage of phosphatidylethanolamine, which is usually found primarily cell membrane associated. The sol-fraction from the CF patient group had a lower percentage of phosphatidylcholine and about 3 times more surfactant protein A than that from the non-CF patients. Surface activity did not differ between CF and non-CF samples. Of interest, the adsorption rate (gamma ads, about 30-35 mN/m) and the minimal surface tension (gamma min, about 20-25 mN/m) were relatively low. These data support the hypothesis that surface active material can be released from sputum and that it might support its transport by reducing mucus adhesiveness to the airways.

Adolescent↗

Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.

Cystic fibrosis (CF) is caused by mutation in the gene for the CF transmembrane conductance regulator which leads to massive, abnormally viscous, purulent sputum, chronic destructive endobronchitis and early death. Purified recombinant human (rh) DNase can digest extracellular DNA and its inhalation in these patients significantly improves lung function. To evaluate the poorly understood mechanisms, saliva protected sputum from patients treated with and without rhDNase were evaluated. Therapy with rhDNase resulted in a soluble sputum fraction that had a higher percentage of phosphatidylethanolamine, a phospholipid present mainly in cellular membranes, a much lower percentage of phosphatidylcholine, but a higher surface activity. The rigidity was significantly lower and the ratio of viscosity in proportion to elasticity increased. All these data are consistent with an increased clearability of the sputum by coughing, but not by mucociliary activity. Thus the interaction of inhaled rhDNase with the purulent mucus and the endobronchial inflammatory processes may induce changes that result in rheological properties favoring clearance of sputum by cough.

Administration, Inhalation↗